Neurophth and AAVnerGene partner on AAV capsids for next-gen ophthalmic gene therapyJanuary 19th 2021
Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.
Gyroscope Therapeutics, UPenn to develop gene therapies for serious eye diseasesJanuary 10th 2021
Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.
Collaboration formed to develop AAV-based gene therapies for eye diseaseJanuary 6th 2021
ViGeneron and Biogen this week have announced a global collaboration and licensing agreement in which the partners will develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors that treat inherited eye disease.